Evaluating the efficacy of upadacitinib in patients with moderate rheumatoid arthritis: a post-hoc analysis of the SELECT phase 3 trials
Philip G. Conaghan(University of Leeds), Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Katie Marchbank(AbbVie (United States)), Toby Kent(Eli Lilly (United Kingdom)), Karel Pavelká(Institute of Rheumatology), Song‐Chou Hsieh(National Taiwan University Hospital), Terri-Leigh Bonnington(AbbVie (United States))
Cited by 5
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
|The Lancet|2004|1.8k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k
EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis
|Annals of the Rheumatic Diseases|2013|1.4k